Demethoxycurcumin Suppresses Human Brain Glioblastoma Multiforme GBM 8401 Cell Xenograft Tumor in Nude Mice In Vivo

Yi-Ping Huang 1, Yi-Shih Ma 2,3, Chao-Lin Kuo 4, Ching-Lung Liao 5, Po-Yuan Chen 6,*, Shu-Fen Peng 6,7, Fei-Ting Hsu 6,8,* and Kuang-Chi Lai 8,9,*

Abstract: Demethoxycurcumin (DMC), a derivate of curcumin, has been shown to induce apoptotic cell death in human glioblastoma multiforme GBM 8401 cells via cell cycle arrest and induction of cell apoptosis. However, there is no report showing DMC suppresses glioblastoma multiforme cells in vivo. In the present study, we investigated the effects of DMC on GBM8401 cells in vivo. At first, we established a luciferase-expressing stable clone named GBM 8401/luc2. Second, mice were inoculated subcutaneously with GBM 8401/luc2 cells to generate a xenograft tumor mice model. After inoculation, tumor volume reached 100–120 mm³, and all mice were randomly divided into three groups: Group I was treated with 110 µL phosphate-buffered solution (PBS) containing 0.1% dimethyl sulfoxide, Group II with 30 mg/kg of DMC, and Group III with 60 mg/kg of DMC. Mice from each group were given the oral treatment of DMC by gavage for 21 days. The body weight and tumor volume were recorded every 3 days. DMC significantly decreased the tumor volumes, and 60 mg/kg treatment showed a higher decrease in tumor volumes than that of 30 mg/kg. However, DMC did not affect the body weights. The photons emitted from mice tumors were detected with Xenogen IVIS imaging system, DMC at both doses decreased the total photon flux and 60 mg/kg treatment of DMC was lower than that of 30 mg/kg. Furthermore, the hematoxylin and eosin (H&E) staining of liver tissues showed no significant difference between DMC-treated and control groups. Overall, these observations showed that DMC suppressed tumor properties in vivo and DMC may be used against human glioblastoma multiforme in the future.

Keywords: demethoxycurcumin (DMC); glioblastoma multiforme; xenograft tumor; nude mice; in vivo
1. Introduction

Gliomas, which originate in the parenchyma of the central nervous system (CNS), are the most common type of adult primary brain tumors. Gliomas are also the most common CNS neoplasms, which are characterized by aggressive growth, high malignant degree, and poor prognosis. There are three subtypes of human gliomas, such as astrocytomas, oligodendrogliomas, and ependymomas. Glioblastoma resides within the category of astrocytoma [1]. The World Health Organization (WHO) divides gliomas into Grade I pilocytic astrocytoma, Grade II diffuse astrocytoma, Grade III anaplastic astrocytoma, and Grade IV glioblastoma [2,3]. Grades III and IV represent the majority of brain tumors [4]. The glioblastoma (GBM) shows a poor prognosis.

Curcuminoids, polyphenol pigment compounds, are the turmeric’s main active ingredients, which are extracted from the *Curcuma longa* rhizome. Curcuminoids contain three major bioactive ingredients, including curcumin (CUR), demethoxycurcumin (DMC), and bisdemethoxycurcumin (BDMC), which are in a ratio of 77:17:3 [5]. CUR has biological activities such as anti-inflammatory, antioxidant, and anti-cancer [6–9], anti-arthritic and lipid-modifying [10], and analgesic and immune-regulatory [11]. Still, its poor solubility in water and easy degradation in vitro and in vivo limit its applications [12]. DMC has similar biological properties to CUR, but it is chemically stable [13]. DMC showed the most potent inhibition of excision repair cross-complementation 1 (ERCC1), which plays a significant role in the incision at the 5′ site of damaged DNA from cisplatin treatment when compared to other curcuminoids [14].

Numerous studies have shown that DMC inhibited cell proliferation in many human cancer cells. DMC induced cell apoptosis in human prostate cancer cells, brain malignant glioma GBM 8401 cells, and skin cancer cells [15–17]. Besides, it induced DNA damage and apoptosis in human lung cancer NCI-H460 cells and oral cancer SCC-4 cells [18–20]. Moreover, DMC was more efficient than TMZ on anti-gliomas and glioma stem cells (GSCs) [21–23].

Although DMC has been shown to retard the growth of GBM 8401 cells and induced cell apoptosis in vitro [16]. However, there is no available information to show DMC affects GBM 8401 cells in vivo. Thus, the current study aims to investigate the effects of DMC on the GBM 8401 cell xenograft mice model in vivo and results indicated DMC significantly reduced tumor growth in vivo.

2. Results

2.1. DMC Markedly Inhibited Glioblastoma Tumor Growth

To examine the anti-tumor effects of DMC, we established human glioblastoma (GBM 8401 cells) bearing animal models. The animal experiment flow chart was displayed in Figure 1A. DMC was used to treated glioblastoma mice for 21 days and mouse tumor size was measured by caliper every three days. At the end of treatment, mice were sacrificed and tumors were removed. After treatment of DMC, mouse tumor growth was effectively suppressed and a significant difference was found from day 6 at high dose (60 mg/kg) of DMC treatment (Figure 1B). In Figure 1C,D, tumors were excised, photographed, and weighed on day 21, and the low (30 mg/kg) and high dose (60 mg/kg) of DMC both can reduce the size and weight of tumors.

2.2. DMC Markedly Reduced the Signal Intensity of Luc2 from Glioblastoma-Bearing Mice

Luc2 signal of the tumor, which represents tumor growth, was collected by BLI every week. Figure 2A shows bioluminescent images of mice from each group on days 0, 7, 14, and 21. Luc2 signal intensity from the control group was increased almost 150 times more as compared to day 0 in the control group (Figure 2B). The low dosage (30 mg/kg) of DMC and high dosage (60 mg/kg) both effectively delayed the luc2 intensity growth in glioblastoma tumors. As compared to the low dosage of DMC, the high dosage of DMC...
showed superior tumor inhibition capacity, showing weak luc2 signals. Furthermore, these results were consistent with the tumor size data.

Figure 1. Tumor growth was inhibited by DMC treatment. (A) An animal experiment flow chart was displayed. (B) Tumor volume was measured by caliper every three days and quantified. (C) Tumors were isolated and photographed from each group of mice on day 21. (D) Tumor weight was also measured and quantified. (a1 \( p < 0.05 \) and a2 \( p < 0.01 \) vs. control; b1 \( p < 0.05 \) and b2 \( p < 0.01 \) vs. DMC 30 mg/kg).

Figure 2. Luc2 signals from living tumor cells were suppressed by DMC treatment. (A) The representative BLI results from each group at different time points. (B) Quantification results of luc2 signal intensity of tumors. (a2 \( p < 0.01 \) vs. control; b1 \( p < 0.05 \) and b2 \( p < 0.01 \) vs. DMC 30 mg/kg).
2.3. DMC Suppressed Anti-Apoptosis and Induced Apoptosis Factors in Glioblastoma-Bearing Mice

Mice were sacrificed on day 21 and then their tumors were isolated for further validation. Here, we performed IHC staining to investigate the alteration of apoptosis-related markers after DMC treatment. First, we investigated the expression of Bcl-2 and XIAP, both of them were recognized as anti-apoptosis markers, which suppressed the tumor apoptosis effect. After DMC treatment, the protein levels of Bcl-2 and XIAP were decreased around 50–80% as compared to control (Figure 3A,B), indicating DMC decreased anti-apoptosis markers. Besides, we also validated whether apoptosis-related factors were induced at the same time. In Figure 3C,D, the levels of cleaved caspase-3 and BAX were increased two to three times more by DMC as compared to control. The evidence suggested that DMC may suppress tumor growth via regulating apoptosis signaling of glioblastoma.

Figure 3. Apoptosis-related proteins were modulated by DMC treatment. (A) The IHC staining images of Bcl-2 and XIAP were observed by microscope with 100 times magnification. (B) Quantification results of Bcl-2 and XIAP protein levels as compared to control. (C) The IHC staining images of cleaved caspase-3 and BAX were observed by microscope with 100 times magnification. (D) Quantification results of cleaved caspase-3 and BAX protein levels as compared to control. (a^2 < 0.01 vs. control; b^1 p < 0.05 vs. DMC 30 mg/kg).

2.4. DMC Treatment Did Not Induce Acute or Delayed Toxicity of Glioblastoma-Bearing Mice

H&E staining of mice liver was performed in order to identify whether the dosage of DMC used in this study may trigger any toxicity in mice. As shown in Figure 4A, no differences in liver tissues were found in the three groups. Additionally, body weight was also used to monitor general toxicity during the treatment period. In Figure 4B, mouse body weight did not change more than 20% at every time point, indicating no signs of acute or delayed toxicity.
Figure 4. No acute or delayed toxicity was found in DMC-treated glioblastoma-bearing mice. (A) Liver pathology photograph from the microscope with 100 times magnification. (B) Mouse body weight was measured and recorded every three days.

3. Discussion

Cancer is still a severe health problem worldwide and it continues to be a leading cause of death in the human population. So far, many plant-derived compounds such as taxol [24], vinblastine [25], and topotecan [26] have been used as anti-cancer drugs for cancer therapy. Around 75% of the clinically used anti-cancer drugs are derived from natural plants, animals, and microorganisms [27], and especially the phytochemicals were used for promising cancer preventative agents and attract research interest [28–30]. Numerous studies have shown that DMC induced cell apoptosis in many human cancer cells in vitro [15–20], including human brain malignant glioma GBM 8401 cells [16]. However, DMC’s anti-tumor activity on the human malignant glioma xenograft mouse model had no available information. Therefore, we used athymic nude mice inoculated with GBM 8401/luc2 cells for investigating the inhibitory effects of DMC on the growth of GBM 8401 cell xenograft tumor for further clinical use in the future. The whole overall outline of these experiments is shown in Figure 1A.

During the treatment, individual tumor size from each treatment (0, 30, and 60 mg/kg of DMC) was measured by caliper every three days and luc2 signal of the tumor was acquired from BLI every week for treatment of DMC on glioblastoma mice up to 21 days. Results indicated that DMC at both doses significantly reduced tumor volume compared to control and the group at the higher dose of DMC showed higher inhibition of tumor volume than that of the lower (Figure 1B). At the end of treatment, all mice were sacrificed and the tumors were isolated, photographed, and weighted from each mouse of each group and the results are shown in Figure 1C,D. Results indicated that a low dose (30 mg/kg) and a high dose (60 mg/kg) of DMC both could reduce the size and weight of tumors when compared to control (Figure 1C,D). These results indicated that DMC at both doses significantly reduced tumor weights in mice. For the orthotopic glioblastoma xenograft mode, the anti-tumor effects of DMC are not better than temozolomide (the first-line clinical drug for the treatment of brain cancer) [31]. Thus, we will develop nanoparticles loaded with DMC for penetrating the blood-brain barrier.

Twelve mice were inoculated subcutaneously with GBM 8401/luc2 cells and randomly separated into three groups (control, 30 mg/kg and 60 mg/kg of DMC groups) and followed by Xenogen IVIS imaging system 200 to detect the photons emitted from mouse tumor. The Xenogen IVIS imaging system is suitable for examining the effects of test chemicals on inhibiting tumor growth in xenograft animal models [32]. The represented bioluminescent imaging of mice from each group on days 0, 7, 14, and 21 was displayed using the Xenogen IVIS imaging system (Figure 2A). Luc2 signal intensity from the control group increased almost 150 times more than day 0 (Figure 2B). Both doses of DMC effectively delay the Luc2 intensity growth in glioblastoma tumors. The higher dose (60 mg/kg) of DMC has higher inhibition of luc2 signal than the lower dose (30 mg/kg). Furthermore, this result was consistent with tumor size data. These observations indicated DMC inhibited the tumor
growth in vivo, moreover, DMC significantly reduced tumor volumes and weights (Figure 1B-D) and a higher dose of DMC has a higher inhibition of tumor growth in vivo. It was reported that DMC played a major role against heavy metal-induced neurotoxicity and has neuroprotective properties [33]. Herein, results clearly indicated that the administration of DMC (30 and 60 mg/kg) delayed brain tumor development in xenograft animal models. DMC was superior to TMZ in its ability to inhibit cell proliferation and induce apoptosis of GSCs in vitro and in vivo [34]. Therefore, we may suggest that DMC may have the potential to develop against brain tumors in the future.

In order to further investigate regarding DMC reduced the growth of GBM 8401/luc2 cell xenograft tumor in nude mice, after treatment, all tumors were collected, stained, and conducted by immunohistochemical analysis. We selected the expressions of anti-apoptotic proteins such as Bcl-2 and X-linked inhibitor of apoptosis (XIAP) and pro-apoptotic proteins such as caspase-3 and Bax for evaluating the DMC’s apoptosis effects. The procaspase levels decreased via the formation of cleaved-caspases during the activation of caspases [35] and apoptosis is regulated by BAX and Bcl-2 (apoptosis-related protein), known as Bcl-2 family members [36]. Results indicated that DMC significantly inhibited the expressions of Bcl-2 and XIAP (Figure 3A,B). Bcl-2 is well documented that is an anti-apoptotic protein and its level decreased will lead to apoptosis. XIAP protein mediates chemotherapy resistance and apoptosis resistance [37] and it is a potent inhibitor of cell death that involved the inhibition of specific caspases [27]. Herein, our findings also showed that XIAP might be one of the mechanisms for reduced tumor weights and volume in the GBM 8401 cell xenograft tumor mice model.

Herein, we showed the effects of oral administration of DMC (0, 30, and 60 mg/kg) on the tumor growth of GBM 8401/luc2 cell xenograft animals and results showed that DMC did not significantly affect the body weights (Figure 4A,B). Furthermore, we examined the liver samples with or without DMC treatment and results indicated no cytotoxicity in liver tissues on all tested animals. Based on these observations, DMC is a suitable and potential compound for further investigation related to anti-glioma in vivo.

In summary, overall results showed reduced growth of the GBM 8401 cell xenograft tumor, including the reduction of the tumor volumes and weights by DMC through the induction of apoptosis, based on markedly decreased Bcl-2 and XIAP but significantly increased the cleaved caspase-3 and BAX in tumor tissues from the immunohistochemistry of tumor sections in the DMC treatment groups. Our findings could contribute to a better understanding of human glioblastoma’s molecular mechanisms after exposure to DMC. Thus, it may provide additional targets for developing the new target therapies associated with GBM patient outcomes in the future.

4. Materials and Methods

4.1. Chemicals and Reagents

Demethoxycurcumin (DMC) was bought from ChemFaces (Wuhan, China) and prepared as 150 mg/mL stock by dimethyl sulfoxide (DMSO) (Sigma Chemical Co., St. Louis, MO, USA). Hygromycin B was obtained from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA).

4.2. Cell Culture of Human Glioblastoma GBM8401 Cells

The human glioblastoma cell line (GBM 8401 cells, successfully established from Chinese female with brain glioblastoma multiforme) [38] was obtained from the Food Industry Research and Development Institute (Hsinchu, Taiwan). GBM 8401 cells were maintained in RPMI-1640 (Life Technologies, Carlsbad, CA, USA) containing 10% heat-inactivated fetal bovine serum (FBS) (Hyclone Laboratories, Logan, UT, USA), 2 mM L-glutamine, and antibiotics (100 U/mL penicillin and 100 µg/mL streptomycin) in a 10-cm culture dish in a humidified atmosphere of 5% CO₂ incubator at 37 °C [39].
4.3. Cell Transfection and Stable Clone Selection

Before transfection, confluency of at least 80% of GBM 8401 cells was reached before the transfection procedure. JetPEI™ transfection reagents and pGL4.50 luciferase reporter (pGL4.50 [luc2/CMV]) vector were obtained from Polyplus Transfection (Illkirch, Bas-Rhin, France) and Promega (Madison, WI, USA), respectively. According to the manufacture protocol, the detailed transfection and stable clone selection methods were described in our previous studies [40,41]. After transfection, hygromycin B (200 µg/mL) was used to screen and maintain luc2 expression in GBM 8401 cells. GBM 8401 cells with luc2 signals were selected by IVIS 200 Imaging System (Xenogen, Alameda, CA, USA) and identified as GBM 8401/luc2 cells.

4.4. Xenograft GBM 8401 Bearing Animal Model

Twelve male athymic CAnN.Cg-Foxn1nu/CrlNarl (NUDE), 6–8 weeks old, were purchased from the National Laboratory Animal Center (Taipei, Taiwan). The animals were maintained in standard cages in a filtered airflow at 25 °C. China Medical University had approved the study (CMU 2019-204). Animals were allowed to acclimate for 7 days, then GBM 8401/luc2 cells (1 × 10⁷ cells/mouse) were subcutaneously injected into each mouse’s right flank to form a glioblastoma animal model [40,41].

4.5. Treatment and Physical Tumor Growth Validation

The tumor size of each animal was measured every three days using calipers. After the tumor grew for 14 days and its size reached an average of 100 mm³, twelve mice were randomly separated into three groups: Control (0.1% DMSO), 30 or 60 mg/kg of DMC groups. The animal study was schematized in Figure 1. Treatment drugs were diluted in 100 µL PBS containing 0.1% DMSO and administered by gavage daily. Tumor volume was measured by digital caliper and calculated by the equation: V = L × W² × 0.523 (where V is the volume, L is the length, and W is the width) [40,41]. Tumors from each mouse were removed, photographed, and weighed after 21 days’ treatment.

4.6. In Vivo Bioluminescent Imaging (BLI)

Mice from each group were intraperitoneally injected with 150 mg/kg D luciferin (Promega, Madison, WI, USA), 15 min before being anesthetized using 1–3% isoflurane for BLI scanning. Image acquisition was performed by IVIS 200 Imaging System and luc2 signal intensity was quantified by Living Image software (Version 2.20, Xenogen, Alameda, CA, USA) [41].

4.7. Liver Pathology and Tumor Immunohistochemistry Staining

The liver and tumor tissue isolated from mice were fixed with 10% neutral buffered formalin and embedded by paraffin. The liver tissue section stained with hematoxylin and eosin (H&E) was used as an anatomical pathology diagnosis to compare untreated and DMC-treated mice [42]. Tumor immunohistochemistry staining of Bcl-2, XIAP, cleaved caspase-3, and BAX was performed as previously described [41]. In brief, tumor sections from the individual group of mice were incubated with primary monoclonal anti-Bcl-2 (1:300 dilution; Cell Signaling, MA, USA), anti-XIAP (1:300 dilution; Elabscience Biotechnology Inc., Houston, TX, USA), anti-cleaved caspase-3 (1:300 dilution; Cell signaling, Danvers, MA, USA), and anti-BAX antibodies (1:300 dilution; Rosemont, IL, USA) at 4 °C overnight. Then, followed with secondary antibodies staining for 1 hr and wash twice by rinse buffer before Horseradish Peroxidase Streptavidin (HRP Streptavidin) inoculation. Finally, slides were dehydrated, stabilized with mounting medium, and scanned by Nikon ECLIPSE Ti-U microscope (×100 magnification, Nikon Instruments Inc., Melville, NY, USA). A total of five view images was quantified by Image J and used to represent the protein level alteration (version 1.50, National Institutes of Health, Bethesda, MD, USA) [43]. Image was quantified by Image J IHC tool box developed. The procedure of analysis was followed by the proto-
4.8. Statistical Analysis

Data are all expressed as mean ± standard error. Comparison between two groups was performed using one-way ANOVA by GraphPad prism 7 software (San Diego, CA, USA). The p value of less than 0.05 was considered to indicate statistical significance.

Author Contributions: Y.-P.H., F.-T.H. and K.-C.L. conceived the project; Y.-P.H., performed the experiments; Y.-S.M., C.-L.K., C.-L.L., P.-Y.C. and S.-F.P. analyzed the bioinformatics analyses; F.-T.H. and K.-C.L. wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by a grant from the China Medical University, Taichung, Taiwan (grant number: CMU107-TU-05) and Ministry of Science and Technology, Taipei, Taiwan (grant number: MOST 109-2314-B-039-021-MY3).

Institutional Review Board Statement: Institutional animal care and use committee in China Medical University had approved the study (ID: CMU 2019-204).

Informed Consent Statement: Not applicable.

Data Availability Statement: The data generated and analyzed will be made available from the corresponding author on reasonable request.

Acknowledgments: Experiments and data analysis were performed in part through the use of the Medical Research Core Facilities Center, Office of Research & Development at China Medical University, Taichung, Taiwan, ROC.

Conflicts of Interest: We wish to confirm that there are no known conflict of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

Abbreviations

Bcl-2, B-cell lymphoma 2; BDMC, bisdemethoxycurcumin; BLI, bioluminescent imaging; CNS, central nervous system; CUR, curcumin; DMC, demethoxycurcumin; DMSO, dimethyl sulfoxide; ERCC1, excision repair cross-complementation 1; FBS, fetal bovine serum; GBM, glioblastoma; GSCs, glioma stem cells; H&E, hematoxylin and eosin; PBS, phosphate-buffered solution; TMZ, temozolomide; XIAP, X-linked inhibitor of apoptosis protein; WHO, World Health Organization.

References

1. Kumar, V.; Aster, J.C. Robbins Basic Pathology E-Book; Elsevier Health Sciences: Amsterdam, The Netherlands, 2017.
2. Jiang, Y.; Uhrbom, L. On the origin of glioma. Upsala J. Med Sci. 2012, 117, 113–121. [CrossRef] [PubMed]
3. Louis, D.N.; Perry, A.; Reifenberger, G.; von Deimling, A.; Figarella-Branger, D.; Cavenee, W.K.; Ohgaki, H.; Wiestler, O.D.; Kleihues, P.; Ellison, D.W. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. Acta Neuropathol. 2016, 131, 803–820. [CrossRef]
4. Zhang, C.; Bao, Z.; Zhang, W.; Jiang, T. Progress on molecular biomarkers and classification of malignant gliomas. Front. Med. 2013, 7, 150–156. [CrossRef] [PubMed]
5. Chen, H.W.; Huang, H.C. Effect of curcumin on cell cycle progression and apoptosis in vascular smooth muscle cells. Br. J. Pharmacol. 1998, 124, 1029–1040. [CrossRef] [PubMed]
6. Fang, J.; Lu, J.; Holmgren, A. Thioredoxin reductase is irreversibly modified by curcumin: A novel molecular mechanism for its anticancer activity. J. Biol. Chem. 2005, 280, 25284–25290. [CrossRef] [PubMed]
7. Jurenka, J.S. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: A review of preclinical and clinical research. Altern. Med. Rev. A J. Clin. Ther. 2009, 14, 141–153.
8. LoTempio, M.M.; Veen, M.S.; Steele, H.L.; Ramamurthy, B.; Ramalingam, T.S.; Cohen, A.N.; Chakrabarti, R.; Srivatsan, E.S.; Wang, M.B. Curcumin suppresses growth of head and neck squamous cell carcinoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2005, 11, 6994–7002. [CrossRef]
9. Gupta, S.C.; Patchva, S.; Koh, W.; Aggarwal, B.B. Discovery of curcumin, a component of golden spice, and its miraculous biological activities. *Clin. Exp. Pharmacol. Physiol.* 2012, 39, 283–299. [CrossRef] [PubMed]

10. Panahi, Y.; Hosseini, M.S.; Khalili, N.; Naimi, E.; Majeed, M.; Sahebkar, A. Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: A randomized controlled trial and an updated meta-analysis. *Clin. Nutr.* 2015, 34, 1101–1108. [CrossRef] [PubMed]

11. Mirzaei, H.; Naseri, G.; Rezaee, R.; Mohammadi, M.; Banikazemi, Z.; Mirzaei, H.R.; Salehi, H.; Peyvandi, M.; Pawelek, J.M.; Sahebkar, A. Curcumin: A new candidate for melanoma therapy? *Int. J. Cancer* 2016, 139, 1683–1695. [CrossRef]

12. Jankun, J.; Wygansowska-Swiatkowska, M.; Dettlaff, K.; Jelinska, A.; Surdacka, A.; Wiatrowska-Swieltlikowska, D.; Skrzypeczak-Jankun, E. Determining whether curcumin degradation/condensation is actually bioactivation (Review). *Int. J. Mol. Med.* 2016, 37, 1151–1158. [CrossRef] [PubMed]

13. Tamvakopoulos, C.; Dimas, K.; Sofianos, Z.D.; Hatziantoniou, S.; Han, Z.; Liu, Z.L.; Wyche, J.H.; Pantazis, P. Metabolism and anticancer activity of the curcumin analogue, dimethoxycurcumin. *Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.* 2007, 13, 1269–1277. [CrossRef] [PubMed]

14. Galluzzo, L.; Senovilla, L.; Vitale, I.;Michels, J.; Martins, I.; Kepp, O.; Castedo, M.; Kroemer, G. Molecular mechanisms of cisplatin resistance. *Oncogene* 2012, 31, 1869–1883. [CrossRef]

15. Ni, X.; Zhang, A.; Zhao, Z.; Shen, Y.; Wang, S. Demethoxycurcumin inhibits cell proliferation, migration and invasion in prostate cancer cells. *Oncof. Rep.* 2012, 28, 85–90. [CrossRef]

16. Huang, T.Y.; Hsu, C.W.; Chang, W.C.; Wang, M.Y.; Wu, J.F.; Hsu, Y.C. Demethoxycurcumin retards cell growth and induces apoptosis in human brain malignant glioma GBM 8401 cells. *Evid.-Based Complementary Altern. Med.* 2012, 2012, 396973. [CrossRef]

17. Wu, Y.; Zhang, P.; Yang, H.; Ge, Y.; Xin, Y. Effects of demethoxycurcumin on the viability and apoptosis of skin cancer cells. *Mol. Med. Rep.* 2017, 16, 539–546. [CrossRef] [PubMed]

18. Ko, Y.C.; Lien, J.C.; Liu, H.C.; Hsu, S.C.; Lin, H.Y.; Chueh, F.S.; Ji, B.C.; Yang, M.D.; Hsu, W.H.; Chung, J.G. Demethoxycurcumin-induced DNA damage decreases DNA repair-associated protein expression levels in NCI-H460 human lung cancer cells. *Anticancer Res.* 2015, 35, 2691–2698. [CrossRef]

19. Ko, Y.C.; Lien, J.C.; Liu, H.C.; Hsu, S.C.; Ji, B.C.; Yang, M.D.; Hsu, W.H.; Chung, J.G. Demethoxycurcumin induces apoptosis in human lung cancer NCI-H460 cells through the mitochondrial-dependent pathway. *Oncof. Rep.* 2015, 33, 2429–2437. [CrossRef]

20. Hsiao, Y.T.; Kuo, C.L.; Chueh, F.S.; Liu, K.C.; Bau, D.T.; Chuang, J.G. Curcuminoids induce reactive oxygen species and autophagy to enhance apoptosis in human oral cancer cells. *Am. J. Chin. Med.* 2018, 46, 1145–1168. [CrossRef]

21. Shi, L.; Fei, X.; Wang, Z. Demethoxycurcumin was prior to temozolomide on inhibiting proliferation and induced apoptosis of glioblastoma stem cells. *Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med.* 2015, 36, 7107–7119. [CrossRef] [PubMed]

22. Leng, L.; Zhong, X.; Sun, G.; Qiu, W.; Shi, L. Demethoxycurcumin was superior to temozolomide in the inhibition of the growth of glioblastoma stem cells in vivo. *Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med.* 2016. [CrossRef] [PubMed]

23. Darling, J.L. *The In Vitro Biology of Human Brain Tumors*; Johns Hopkins University Press: Baltimore, MD, USA, 1990; pp. 1–25.

24. Slichenmyer, W.J.; Von Hoff, D.D. Taxol: A new and effective anti-cancer drug. *Anti-Cancer Drugs* 1991, 2, 519–530. [CrossRef]

25. Caputi, L.; Franke, J.; Farrow, S.C.; Chung, K.; Payne, R.M.E.; Nguyen, T.D.; Dang, T.T.; Soares Teto Carqueijeiro, I.; Koudounas, K.; Duque de Bernonville, T.; et al. Missing enzymes in the biosynthesis of the anticancer drug vinblastine in Madagascar periwinkle. *Science* 2018, 360, 1235–1239. [CrossRef] [PubMed]

26. Brahmer, J.R.; Ettinger, D.S. The role of topotecan in the treatment of small cell lung cancer. *Oncologist* 1998, 3, 11–14. [CrossRef] [PubMed]

27. Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs from 1981 to 2014. *J. Nat. Prod.* 2016, 79, 629–661. [CrossRef] [PubMed]

28. Lee, K.W.; Bode, A.M.; Dong, Z. Molecular targets of phytochemicals for cancer prevention. *Nat. Rev. Cancer* 2011, 11, 211–218. [CrossRef] [PubMed]

29. Rao, C.V.; Kurkjian, C.D.; Yamada, H.Y. Mitosis-targeting natural products for cancer prevention and therapy. *Curr. Drug Targets* 2012, 13, 1820–1830. [CrossRef]

30. Hao, F.; Kumar, S.; Yadav, N.; Chandra, D. Neem components as potential agents for cancer prevention and treatment. *Biochim. Et Biophys. Acta* 2014, 1846, 247–257. [CrossRef]

31. Shi, L.; Sun, G. DMC is not better than TMZ on intracranial anti-glioma effects. *J. Cell Biochem.* 2018, 119, 6057–6064. [CrossRef]

32. Pore, S.K.; Hahn, E.R.; Latocca, J.D.; Anderson, C.J.; Shuai, Y.; Singh, S.V. Prevention of breast cancer-induced osteolytic bone resorption by benzyl isothiocyanate. *Carcinogenesis* 2018, 39, 134–145. [CrossRef]

33. Dairam, A.; Limson, J.L.; Watkins, G.M.; Antunes, E.; Daya, S. Curcuminoids, curcumin, and demethoxycurcumin reduce lead-induced memory deficits in male Wistar rats. *J. Agric. Food Chem.* 2007, 55, 1039–1044. [CrossRef] [PubMed]

34. Chen, Y.Y.; Lin, Y.J.; Huang, W.T.; Hung, C.C.; Lin, H.Y.; Tu, Y.C.; Liu, D.M.; Lan, S.J.; Sheu, M.J. Demethoxycurcumin-loaded chitosan nanoparticle downregulates DNA repair pathway to improve cisplatin-induced apoptosis in non-small cell lung cancer. *Molecules* 2018, 23, 3217. [CrossRef] [PubMed]

35. Florentin, A.; Arama, E. Caspase levels and execution efficiencies determine the apoptotic potential of the cell. *J. Cell Biol.* 2012, 196, 513–527. [CrossRef]
36. Krajewska, M.; Zapata, J.M.; Meinhold-Heerlein, I.; Hedayat, H.; Monks, A.; Bettendorf, H.; Shabaik, A.; Bubendorf, L.; Kallioniemi, O.P.; Kim, H.; et al. Expression of Bcl-2 family member Bid in normal and malignant tissues. *Neoplasia* 2002, 4, 129–140. [CrossRef] [PubMed]

37. Vellanki, S.H.; Grabrucker, A.; Liebau, S.; Proepper, C.; Eramo, A.; Braun, V.; Boeckers, T.; Debatin, K.M.; Fulda, S. Small-molecule XIAP inhibitors enhance gamma-irradiation-induced apoptosis in glioblastoma. *Neoplasia* 2009, 11, 743–752. [CrossRef] [PubMed]

38. Lee, W.H.; Yeh, M.Y.; Tu, Y.C.; Han, S.H.; Wang, Y.C. Establishment and characterization of a malignant glioma cell line, GBM8401/TSGH, NDMC. *J. Surg. Oncol.* 1998, 38, 173–181. [CrossRef] [PubMed]

39. Wang, D.Y.; Yeh, C.C.; Lee, J.H.; Hung, C.F.; Chung, J.G. Berberine inhibited arylamine N-acetyltransferase activity and gene expression and DNA adduct formation in human malignant astrocytoma (G9T/VGH) and brain glioblastoma multiforms (GBM 8401) cells. *Neurochem. Res.* 2002, 27, 883–889. [CrossRef]

40. Ma, Y.S.; Lin, J.J.; Lin, C.C.; Lien, J.C.; Peng, S.F.; Fan, M.J.; Hsu, F.T.; Chung, J.G. Benzyl isothiocyanate inhibits human brain glioblastoma multiforme GBM 8401 cell xenograft tumor in nude mice in vivo. *Environ. Toxicol.* 2018, 33, 1097–1104. [CrossRef]

41. Weng, M.C.; Li, M.H.; Chung, J.G.; Liu, Y.C.; Wu, J.Y.; Hsu, F.T.; Wang, H.E. Apoptosis induction and AKT/NF-κB inactivation are associated with regorafenib-inhibited tumor progression in non-small cell lung cancer in vitro and in vivo. *Biomed. Pharmacother. Biomed. Pharmacother.* 2019, 116, 109032. [CrossRef]

42. Chiu, W.C.; Yang, H.H.; Chiang, S.C.; Chou, Y.X.; Yang, H.T. Auricularia polytricha aqueous extract supplementation decreases hepatic lipid accumulation and improves antioxidative status in animal model of nonalcoholic fatty liver. *BioMedicine* 2014, 4, 12. [CrossRef] [PubMed]

43. Weng, M.C.; Wang, M.H.; Tsai, J.J.; Kuo, Y.C.; Liu, Y.C.; Hsu, F.T.; Wang, H.E. Regorafenib inhibits tumor progression through suppression of ERK/NF-κB activation in hepatocellular carcinoma bearing mice. *Biosci. Rep.* 2018, 38. [CrossRef]

44. Shu, J.; Dolman, G.E.; Duan, J.; Qiu, G.; Ilyas, M. Statistical colour models: An automated digital image analysis method for quantification of histological biomarkers. *Biomed. Eng. Online* 2016, 15, 46. [CrossRef] [PubMed]